Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
37 hedge funds and large institutions have $26.1M invested in Telesis Bio, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 19 reducing their positions, and 18 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less funds holding
Funds holding: 47 → 37 (-10)
44% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 18
72% less capital invested
Capital invested by funds: $92.9M → $26.1M (-$66.8M)
79% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 19
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$2.01M |
| 2 |
Millennium Management
New York
|
+$704K |
| 3 |
PM
Penbrook Management
New York
|
+$162K |
| 4 |
E
Ergoteles
New York
|
+$152K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$119K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Ophir Asset Management
Sydney,
Australia
|
-$7.06M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
-$3.13M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$1.61M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$1.48M |
| 5 |
BlackRock
New York
|
-$1.41M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WTA
51
Washington Trust Advisors
Wellesley,
Massachusetts
| – | -$1K | -12 | Closed |
|
52
Osaic Holdings
Scottsdale,
Arizona
| – | -$207 | -3 | -12% |
|
|
BTI
53
Blue Trust Inc
Alpharetta,
Georgia
| – | +$138 | +2 | New |
|
TBIO Hedge Fund Activity: Q2 2022 in Review
37 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q2 2022, worth a combined $26.1M — down 72% from $92.9M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of TBIO and 10 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 4 added.
The largest buyer was Penn Capital Management, opening a new position worth an estimated $2.01M. The largest seller was Ophir Asset Management, exiting entirely with an estimated $7.06M sold.
- 37 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q2 2022, down from 47 in Q1 2022.
- Funds reported $26.1M of Telesis Bio, Inc. Common Stock stock for Q2 2022, down 72% quarter-over-quarter.
- 10 funds opened new Telesis Bio, Inc. Common Stock positions in Q2 2022 and 18 closed out, a net change of -8 holders.
- The largest Telesis Bio, Inc. Common Stock buyer in Q2 2022 was Penn Capital Management, an estimated $2.01M added.
- The largest Telesis Bio, Inc. Common Stock seller in Q2 2022 was Ophir Asset Management, an estimated $7.06M sold.
Based on aggregated 13F filings for Q2 2022.